Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
SARS-CoV-2 Mpro 抑制剂 RAY1216 的临床前评估显示,与尼玛瑞韦相比,其药代动力学有所改善
期刊:Nature Microbiology
影响因子:20.5
doi:10.1038/s41564-024-01618-9
Xiaoxin Chen #, Xiaodong Huang #, Qinhai Ma #, Petr Kuzmič #, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin